Document is current
Any future updates will be listed below
-
Authors
Rapoport, Bernardo Leon
Aapro, Matti
Paesmans, Marianne
van Eeden, Ronwyn
Smit, Teresa
Krendyukov, Andriy
Klastersky, Jean
-
Funding
Funding for this research was provided by:
Hexal AG
- License Information
-
More Information
Article History
Received: 18 December 2017
Accepted: 19 September 2018
First Online: 24 September 2018
Ethics approval and consent to participate
: The study protocol was approved by Pharma-Ethics, reference number 161115075. ExternalRef removed.This ethical approval covers all participating centers in all countries. Each participating site was subject to ethical approval by the Institutional Research Ethics Committee and commits to conduct the study according to local conditions (informed consent, protection of patient right and data confidentiality, insurance).Eligible participants may only be included in this study after providing written, IEC approved informed consent.
: Not applicable.
: This study is funded by Hexal AG.BR reports grants from Sandoz, personal fees from Amgen South Africa, Roche Malaysia, Teva, and Cipla South Africa. MA reports personal fees from Helsinn Healthcare, Teva, Hospira, Merck KGaA, Merck, Sandoz, Pierre Fabre, Vifor Pharma, Tesaro, Amgen, Novartis, Roche, and Johnson & Johnson. AK is an employee of Hexal AG (a Sandoz company). All other authors have declared no conflicts of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
